No abstract

Arthritis is a common condition among the working population in the United States. Despite its high prevalence, the total cost of arthritis from the employer perspective has not been fully evaluated. This study quantifies the employer cost for additional health care, absence, disability, productivity, and workers' compensation costs related to arthritis and associated joint disorders (AJD) for a large sample of employees over 4 years. Results showed that AJD affected 15.5% of the employee population at some time. After adjusting for confounding factors, employees with AJD had significantly higher costs for health care ($998), prescription drug ($195), absence ($84), short-term disability ($184), long-term disability ($54), and workers' compensation ($287); totaling $1802. Adjusted productivity output was 4% lower for the AJD group, equal to $7454 in lost revenue (P < .05). Implications for an aging workforce are also discussed.

No abstract

Current literature about the long-term impacts of corporate health and wellness programs has brought to light new evidence about the cost savings associated with health-promotion interventions. A critical element in these initiatives is attracting the participation of employees at risk for high benefits use. This study presents evidence that suggests accomplishing this task has economic savings implications to large employers. A health and wellness intervention program offered at GlaxoSmithKline, entitled the Contract for Health and Wellness, is examined. Focusing on a group of 6049 employees, the study examines the impact on health behaviors and on integrated health benefits use of this continuously employed population from 1996 to 2000. Total benefits costs are examined for participants and nonparticipants, and the annual savings associated with the isolated impact of the program are, on average, $613 per participant. Reductions in disability costs accounted for the majority of these savings.